Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

Safety and in vivo immune assessment of escalating doses of oral laquinimod in patients with RRMS

Abstract Background Laquinimod is an oral immunomodulator in clinical development to treat relapsing-remitting multiple sclerosis (RRMS). Laquinimod is in clinical development for the treatment of multiple sclerosis and Huntington Disease (HD). The objective of this study is to assess the safety, to...

Full description

Bibliographic Details
Main Authors: Tjalf Ziemssen, Hayrettin Tumani, Tony Sehr, Katja Thomas, Friedemann Paul, Nils Richter, Emil Samara, Ofer Spiegelstein, Ella Sorani, Oren Bar-Ilan, Dorit Mimrod, Liat Hayardeny
Format: Article
Language:English
Published: BMC 2017-08-01
Series:Journal of Neuroinflammation
Subjects:
Laquinimod
Multiple sclerosis
Safety
Immunology
slanDC
Online Access:http://link.springer.com/article/10.1186/s12974-017-0945-z

Internet

http://link.springer.com/article/10.1186/s12974-017-0945-z

Similar Items